Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])

Plain-language summary

This study investigates biomarkers related to genetic susceptibility in children with neuroblastoma (a childhood nerve tissue tumor). It included children diagnosed with neuroblastoma before age 6 and their biological mothers. It is an observational (non-phase) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Children's Oncology Group

Intervention

Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration

Start date

2/3/2009

Estimated completion

12/31/2018

Countries

United States, Canada

Related genes

Locations

• Birmingham, United States
• Mobile, United States
• Phoenix, United States
• Little Rock, United States
• Downey, United States
• Loma Linda, United States
• Long Beach, United States
• Los Angeles, United States
• Los Angeles, United States
• Oakland, United States
• Oakland, United States
• Orange, United States
• Palo Alto, United States
• Sacramento, United States
• San Diego, United States
• San Francisco, United States
• Santa Barbara, United States
• Aurora, United States
• Denver, United States
• Hartford, United States
• New Haven, United States
• Wilmington, United States
• Washington D.C., United States
• Washington D.C., United States
• Fort Lauderdale, United States
• Gainesville, United States
• Hollywood, United States
• Jacksonville, United States
• Miami, United States
• Orlando, United States
• Orlando, United States
• Pensacola, United States
• St. Petersburg, United States
• Tampa, United States
• West Palm Beach, United States
• Atlanta, United States
• Augusta, United States
• Savannah, United States
• Boise, United States
• Chicago, United States

+113

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Primary diagnosis of neuroblastoma made at a North American COG institution
* Diagnosed between 12/24/2007- 7/31/2013
* Diagnosed at \< 6 years of age
* Biological mother is alive and willing to participate
* Questionnaire respondents must understand English or Spanish
* Are only those participating in CCRN who have agreed to be contacted for future studies